首页> 美国卫生研究院文献>AIDS Research and Treatment >Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India
【2h】

Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India

机译:来自印度北部的抗逆转录病毒治疗纯朴人群中HIV 1型分离株中HIV耐药突变的患病率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. The increased use of antiretroviral therapy (ART) has reduced the morbidity and mortality associated with HIV, adversely leading to the emergence of HIV drug resistance (HIVDR). In this study we aim to evaluate the prevalence of HIVDR mutations in ART-naive HIV-1 infected patients from northern India. Design. Analysis was performed using Viroseq genotyping system based on sequencing of entire protease and two-thirds of the Reverse Transcriptase (RT) region of pol gene. Results. Seventy three chronic HIV-1 infected ART naïve patients eligible for first line ART were enrolled from April 2006 to August 2008. In 68 patients DNA was successfully amplified and sequencing was done. 97% of HIV-1 strains belonged to subtype C, and one each to subtype A1 and subtype B. The overall prevalence of primary DRMs was 2.9% [2/68, 95% confidence interval (CI), 0.3%–10.2%]. One patient had a major RT mutation M184V, known to confer resistance to lamivudine, and another had a major protease inhibitor (PI) mutation D30N that imparts resistance to nelfinavir. Conclusion. Our study shows that primary HIVDR mutations have a prevalence of 2.9% among ART-naive chronic HIV-1 infected individuals.
机译:目的。抗逆转录病毒疗法(ART)的使用增加已降低了与HIV相关的发病率和死亡率,从而不利地导致了HIV耐药性(HIVDR)的出现。在这项研究中,我们旨在评估印度北部来自首次接受ART的HIV-1感染患者中HIVDR突变的患病率。设计。使用Viroseq基因分型系统,基于整个蛋白酶和pol基因三分之二的逆转录酶(RT)区域的测序,进行了分析。结果。从2006年4月至2008年8月,纳入73例接受一线抗病毒治疗的初次接受HIV-1感染的慢性初治患者。在68例患者中,成功扩增了DNA,并进行了测序。 HIV-1毒株中有97%属于C亚型,而分别属于A1亚型和B亚型。原发性DRM的总体患病率为2.9%[2 / 68,95%置信区间(CI),0.3%–10.2%] 。一名患者患有严重的RT突变M184V,已知对拉米夫定具有抗药性,另一名患者患有主要的蛋白酶抑制剂(PI)突变D30N,赋予了对奈非那韦的抗性。结论。我们的研究表明,在未接受ART治疗的慢性HIV-1感染者中,主要的HIVDR突变患病率为2.9%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号